Skip to main content
. 2018 Feb 1;20(5):621–631. doi: 10.1093/neuonc/noy008

Fig. 5.

Fig. 5

SYK regulates tumor proliferation and progression in vivo. (A) Kaplan–Meier survival analysis of immune-compromised mice orthotopically injected with U87MG cells overexpressing eGFP or SYK mutants; n > 5. (B) Representative images of brains and tumors from orthotopically injected U87MG cells overexpressing eGFP, wild type, KD, Y629/630/631F, or Y296/323/348/352F. (C) Ki67 expression of eGFP, wild type, KD, and Y629/630/631F tumor. Bar chart depicts amount of Ki67-positive cells outside the tumor mass in relation to every 10 cells at the tumor front. (D) Kaplan–Meier survival analysis of mice orthotopically injected with U87MG cells either mock-treated (red) or treated with Pic 20 mg/kg 3 times per week (blue) or BAY 5 mg/kg/daily (green). (E) Bioluminescence of mice orthotopically injected with U87MG cells either mock-treated or treated with Pic 20 mg/kg 3 times per week or BAY 5 mg/kg/daily on day 31 (mock: 1.480e+10, 4.911e+09, 1.215e+10, and 1.857e+08; BAY: 1.730e+09, 4.156e+08, 2.493e+08, and 1.857e+08; piceatannol: 6.576e+08, 8.871e+09, 1.1138e+10, 2.262e+10, and 4.933e+08) and day 35 (BAY: 3.729e+08, 1.352e+09, and 4.860e+08; piceatannol: 9.792e+08 and 5.803e+08); n > 8. (F) Caspase-3 and Ki67 IHC of mice orthotopically injected with U87MG cells either mock-treated or treated with Pic 20 mg/kg 3 times per week or BAY 5 mg/kg/daily.